FBIO Fortress Biotech Inc.

1.8
-0.01  -1%
Previous Close 1.81
Open 1.84
Price To Book 3.91
Market Cap 124,276,340
Shares 69,042,411
Volume 49,841
Short Ratio
Av. Daily Volume 363,345

NewsSee all news

  1. Mustang Bio to Present at Scientific Conferences in September 2019

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  2. Fortress Biotech to Present at September 2019 Investor Conferences

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  3. Mustang Bio to Present at September 2019 Investor Conferences

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  4. Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  5. Mustang Bio and St. Jude Children's Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

    RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine  Designation to facilitate expedited development and review of MB-107 for XSCID NEW YORK and MEMPHIS, Tenn.,

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Further Phase 1/2 data due by end of 2019. Phase 3 trial to be initiated in 2020.
CK-101
Non-small cell lung cancer (NSCLC) and other solid tumors
Phase 1 readout due 2019.
MB-101
Glioblastoma
Phase 2b/3 trial to be initiated in 2020 with data due in 2021.
CAEL‐101
AL amyloidosis
Phase 2 data in adults due 2021.
CEVA101
Severe Traumatic Brain Injury
Phase 2 data in children due 2020.
CEVA101
Severe Traumatic Brain Injury
NDA filing due 1H 2020.
CUTX-101
Menkes disease
NDA filing due YE 2019.
Intravenous (IV) tramadol
Postoperative pain following bunionectomy surgery
Phase 1/2 trial ongoing. Initial data noted in NEJM.
MB-107
X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 initial data due 2019.
MB-106
B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial to be initiated 1H 2020.
Triplex
Cytomegalovirus (CMV)
Phase 1/2 trial to be initiated late 2019 or 2020.
MB-104
Multiple myeloma
Phase 1 trial ongoing.
MB-103
HER2-Positive Breast Cancer with Brain Metastases

Latest News

  1. Mustang Bio to Present at Scientific Conferences in September 2019

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  2. Fortress Biotech to Present at September 2019 Investor Conferences

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and

  3. Mustang Bio to Present at September 2019 Investor Conferences

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  4. Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into

  5. Mustang Bio and St. Jude Children's Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

    RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine  Designation to facilitate expedited development and review of MB-107 for XSCID NEW YORK and MEMPHIS, Tenn.,